Nirsevimab's RSV Protection Wanes After First Year, Study Finds

The monoclonal antibody nirsevimab, commercially known as Beyfortus, has demonstrated robust efficacy in safeguarding infants against hospitalizations directly attributable to respiratory syncytial virus (RSV) during their initial year of life. However, a recent analysis has indicated that this protective shield does not extend into the second year following administration. Furthermore, the study found no discernible benefit of nirsevimab for other types of hospitalizations beyond those specifically caused by RSV.

Nirsevimab represents a significant advancement in RSV prevention, functioning as a long-acting antibody designed to confer passive immunity. Unlike vaccines that stimulate the body's own immune response, nirsevimab provides pre-formed antibodies that are immediately available to neutralize the RSV virus upon exposure. This approach is particularly crucial for infants, whose immune systems are still developing and who are at a higher risk for severe complications from RSV, including bronchiolitis and pneumonia. The drug secured regulatory approval, including from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), based on compelling evidence from clinical trials, such as the MELODY and nirsevimab-301 studies, which highlighted its substantial ability to reduce the incidence of medically attended RSV lower respiratory tract infections. Initial real-world data and post-marketing surveillance had reinforced its effectiveness during the critical first RSV season after administration.

The latest findings, which were presented at the 33rd European Respiratory Society (ERS) International Congress, scrutinized data from a substantial cohort of infants. The research meticulously examined hospitalization rates within the first 12 months after nirsevimab administration and compared these to rates observed in the subsequent period. While the observed reduction in RSV-related hospitalizations during the initial year was both statistically significant and clinically meaningful, indicating a clear benefit, this protective effect appeared to diminish or become negligible in the second year. This suggests that the duration of immunity conferred by a single dose of nirsevimab is approximately one year, aligning with the typical duration of passively acquired antibodies.

This revelation carries significant implications for public health strategies and clinical practice concerning RSV prevention. Current guidelines, established by organizations like the Centers for Disease Control and Prevention (CDC) in the U.S., generally recommend a single dose of nirsevimab for eligible infants, particularly those born during or entering the RSV season. The new data necessitates a re-evaluation of these recommendations, prompting discussions about the optimal timing of administration and the potential need for booster doses or alternative preventative measures to ensure sustained protection against RSV, especially for infants who remain vulnerable in their second year of life. Further research is essential to elucidate the immunological mechanisms underlying this waning protection and to explore innovative strategies for extending the duration of nirsevimab's benefits or developing novel preventative interventions. Importantly, the study did not report any new or unexpected safety concerns associated with the use of nirsevimab.